{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:46:18Z","timestamp":1771328778126,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The purpose of this study was to evaluate the efficacy of postoperative adjuvant radiotherapy for patients with upper tract urothelial carcinoma (UTUC) who underwent kidney-sparing surgery (KSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed the clinical records of 31 patients with primary UTUC who underwent kidney-sparing surgery (KSS) and who were treated with adjuvant radiotherapy at our center between October 1998 and May 2017. Statistical analyses were performed with SPSS 23.0. The primary endpoints of this study included overall survival (OS) and local recurrence-free survival (LRFS); the secondary endpoints were disease-free survival (DFS) and treatment-related toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up was 58.4 months (range, 12.7-185.3 months), and the median local recurrence time was 59.0 months (range, 7.0-185 months). All of the patients completed radiotherapy on schedule, and no grade 3\u20134 late-stage reaction was observed. The estimated 5-year and 10-year OS, DFS and LRFS rates of the patients were 64.0%, 61.1%, 69.6% and 48.0%, 40.9%, 64.6%, respectively. Univariate analysis showed that age (\u03c72\u2009=\u20094.224, <jats:italic>P<\/jats:italic>\u2009=\u20090.040), R0 resection (\u03c72\u2009=\u20093.949, <jats:italic>P<\/jats:italic>\u2009=\u20090.047), and early stage (I\u2009+\u2009II) (\u03c72\u2009=\u20096.515, <jats:italic>P<\/jats:italic>\u2009=\u20090.011) were associated with good OS; DFS benefit in early stage patients (\u03c72\u2009=\u20096.151, <jats:italic>P<\/jats:italic>\u2009=\u20090.013) and age&lt;70 years old (\u03c72\u2009=\u20095.091, <jats:italic>P<\/jats:italic>\u2009=\u20090.024). Patients with distal ureteral segments had better LRFS than patients with proximal ureteral cancer (\u03c72\u2009=\u20095.248, <jats:italic>P<\/jats:italic>\u2009=\u20090.022). However, multivariate analysis showed that age was the only factor of OS (\u03c72\u2009=\u20094.099, <jats:italic>P<\/jats:italic>\u2009=\u20090.043).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Adjuvant radiotherapy is safe and tolerated, and LRFS was superior in middle and distal ureteral cancer than in proximal ureteral cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02303-7","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T14:02:19Z","timestamp":1689688939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Postoperative adjuvant radiotherapy for patients with upper tract urothelial carcinoma (UTUC) who underwent kidney-sparing surgery (KSS): a single-center study"],"prefix":"10.1186","volume":"18","author":[{"given":"Hui","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuncan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"1","key":"2303_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2303_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupret","year":"2021","unstructured":"Roupret M, Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2020 update. Eur Urol. 2021;79(1):62\u201379.","journal-title":"Eur Urol"},{"issue":"4","key":"2303_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.urology.2010.04.020","volume":"76","author":"R Abouassaly","year":"2010","unstructured":"Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010;76(4):895\u2013901.","journal-title":"Urology"},{"issue":"2","key":"2303_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MOU.0000000000000148","volume":"25","author":"I Lucca","year":"2015","unstructured":"Lucca I, Klatte T, Roupret M, Shariat SF. Kidney-sparing surgery for upper tract urothelial cancer. Curr Opin Urol. 2015;25(2):100\u20134.","journal-title":"Curr Opin Urol"},{"key":"2303_CR5","doi-asserted-by":"crossref","unstructured":"Zhang J, Yang F, Wang M, Niu Y, Chen W, Xing N. Comparison of Radical Nephroureterectomy and Partial Ureterectomy for the Treatment of Upper Tract Urothelial Carcinoma. Biomed Res Int 2018, 2018:2793172.","DOI":"10.1155\/2018\/2793172"},{"issue":"6","key":"2303_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/j.1464-410X.2006.06519.x","volume":"98","author":"RE Zigeuner","year":"2006","unstructured":"Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98(6):1181\u20136.","journal-title":"BJU Int"},{"issue":"3","key":"2303_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.aju.2017.03.006","volume":"15","author":"MM Elawdy","year":"2017","unstructured":"Elawdy MM, Osman Y, Taha DE, Zahran MH, El-Halwagy S, Garba ME, Harraz AM. Risk factors and prognosis of intravesical recurrence after surgical management of upper tract urothelial carcinoma: a 30-year single centre experience. Arab J Urol. 2017;15(3):216\u201322.","journal-title":"Arab J Urol"},{"issue":"1","key":"2303_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.urology.2007.08.054","volume":"71","author":"T Terakawa","year":"2008","unstructured":"Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology. 2008;71(1):123\u20137.","journal-title":"Urology"},{"issue":"9","key":"2303_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","volume":"12","author":"D Schaue","year":"2015","unstructured":"Schaue D, McBride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol. 2015;12(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2303_CR10","first-page":"333","volume":"34","author":"E Jwa","year":"2014","unstructured":"Jwa E, Kim YS, Ahn H, Kim CS, Lee JL, Kim SO. Adjuvant radiotherapy for stage III\/IV urothelial carcinoma of the upper tract. Anticancer Res. 2014;34(1):333\u20138.","journal-title":"Anticancer Res"},{"key":"2303_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1471-2407-11-297","volume":"11","author":"B Chen","year":"2011","unstructured":"Chen B, Zeng ZC, Wang GM, Zhang L, Lin ZM, Sun LA, Zhu TY, Wu LL, Zhang JY, Ji Y. Radiotherapy may improve overall survival of patients with T3\/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer. 2011;11:297.","journal-title":"BMC Cancer"},{"issue":"7","key":"2303_CR12","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21037\/tau-21-291","volume":"10","author":"MZ Liu","year":"2021","unstructured":"Liu MZ, Gao XS, Qin SB, Li XY, Ma MW, Xie M, Lyu F, Wang D. Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma. Transl Androl Urol. 2021;10(7):2929\u201337.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2303_CR13","first-page":"247","volume":"19","author":"K Hu","year":"2012","unstructured":"Hu K, Hou XR,Shen J, Lian XSun, Sh,Zhang. FQ.Treatment results and prognostic analysis of 47 patients with urethral transitional cell carcinoma treated with post-operative adjuvant radiotherapy. Chin J Radiat Oncol. 2012;19(3):247\u20139.","journal-title":"Chin J Radiat Oncol"},{"issue":"1","key":"2303_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","volume":"47","author":"A Trotti","year":"2000","unstructured":"Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2303_CR15","first-page":"1341","volume":"17","author":"YH Chang","year":"2019","unstructured":"Chang YH, Hsiao PJ, Chen GH, Lin CC, Chang CH, Wu HC, Huang CP, Yang CR, Yeh SP. Outcomes of stage II-IV upper-tract urothelial carcinoma and adjuvant chemotherapy for locally advanced cancer. Oncol Lett. 2019;17(1):1341\u20138.","journal-title":"Oncol Lett"},{"issue":"6","key":"2303_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma collaboration. Cancer. 2009;115(6):1224\u201333.","journal-title":"Cancer"},{"issue":"8","key":"2303_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, et al. Effectiveness of Adjuvant Chemotherapy for locally advanced bladder Cancer. J Clin Oncol. 2016;34(8):825\u201332.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2303_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581\u20137.","journal-title":"Eur Urol"},{"issue":"8","key":"2303_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14737140.2018.1481395","volume":"18","author":"Y Freifeld","year":"2018","unstructured":"Freifeld Y, Krabbe LM, Clinton TN, Woldu SL, Margulis V. Therapeutic strategies for upper tract urothelial carcinoma. Expert Rev Anticancer Ther. 2018;18(8):765\u201374.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2303_CR20","first-page":"247","volume":"35","author":"KH Fan","year":"2012","unstructured":"Fan KH, Chen YC, Leung WM, Chuang CK, Pang ST, Hong JH. Adjuvant and salvage radiotherapy for urothelial cell carcinoma of the upper urinary tract: experience in a single institution. Chang Gung Med J. 2012;35(3):247\u201354.","journal-title":"Chang Gung Med J"},{"key":"2303_CR21","doi-asserted-by":"publisher","first-page":"699210","DOI":"10.3389\/fonc.2021.699210","volume":"11","author":"HZ Li","year":"2021","unstructured":"Li HZ, Li X, Gao XS, Qi X, Ma MW, Qin S. Oncological outcomes of adjuvant radiotherapy for partial ureterectomy in Distal Ureteral Urothelial Carcinoma Patients. Front Oncol. 2021;11:699210.","journal-title":"Front Oncol"},{"key":"2303_CR22","doi-asserted-by":"publisher","first-page":"38175","DOI":"10.1038\/srep38175","volume":"6","author":"YC Huang","year":"2016","unstructured":"Huang YC, Chang YH, Chiu KH, Shindel AW, Lai CH. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep. 2016;6:38175.","journal-title":"Sci Rep"},{"issue":"5","key":"2303_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0959-8049(99)00012-X","volume":"35","author":"M Ozsahin","year":"1999","unstructured":"Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999;35(5):738\u201343.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2303_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0090-4295(98)00295-7","volume":"52","author":"MC Hall","year":"1998","unstructured":"Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52(4):594\u2013601.","journal-title":"Urology"},{"issue":"4 Pt 1","key":"2303_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.ju.0000137910.38441.8a","volume":"172","author":"B Czito","year":"2004","unstructured":"Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004;172(4 Pt 1):1271\u20135.","journal-title":"J Urol"},{"issue":"3","key":"2303_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5152\/tud.2018.19677","volume":"44","author":"MM Elawdy","year":"2018","unstructured":"Elawdy MM, Osman Y, Taha DE, El-Halwagy S. Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: a review of 305 patients. Turk J Urol. 2018;44(3):213\u201320.","journal-title":"Turk J Urol"},{"issue":"4","key":"2303_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O\u2019Brien","year":"2011","unstructured":"O\u2019Brien T, Ray E, Singh R, Coker B, Beard R. British Association of Urological Surgeons section of O: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial). Eur Urol. 2011;60(4):703\u201310.","journal-title":"Eur Urol"},{"issue":"4","key":"2303_CR28","first-page":"603","volume":"49","author":"B Guan","year":"2017","unstructured":"Guan B, Cao ZP, Peng D, Li YF, Zhan YH, Liu LB, He SM, Xiong GY, Li XS, Zhou LQ. [Prognostic factors of patients with T2N0M0 upper tract urothelial carcinoma: a single-center retrospective study of 235 patients]. Beijing Da Xue Xue Bao Yi Xue Ban. 2017;49(4):603\u20137.","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"issue":"8","key":"2303_CR29","first-page":"4051","volume":"36","author":"AW Hahn","year":"2016","unstructured":"Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG. Effect of Adjuvant Radiotherapy on Survival in patients with Locoregional Urothelial Malignancies of the Upper urinary tract. Anticancer Res. 2016;36(8):4051\u20135.","journal-title":"Anticancer Res"},{"issue":"4","key":"2303_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/bju.14647","volume":"123","author":"Y Belhadj","year":"2019","unstructured":"Belhadj Y, Grande P, Seisen T, Gobert A, Gomez FD, Cussenot O, Roupret M. Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. BJU Int. 2019;123(4):618\u201323.","journal-title":"BJU Int"},{"issue":"4","key":"2303_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1159\/000499240","volume":"14","author":"T Inamoto","year":"2020","unstructured":"Inamoto T, Matsuyama H, Komura K, Ibuki N, Fujimoto K, Shiina H, Sakano S, Nagao K, Mastumoto H, Miyake M, et al. Tumor Location based segmentation in Upper-Tract Urothelial Carcinoma Impacts on the Urothelial recurrence-free survival: a multi-institutional database study. Curr Urol. 2020;14(4):183\u201390.","journal-title":"Curr Urol"},{"issue":"1","key":"2303_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bju.12801","volume":"116","author":"I Lucca","year":"2015","unstructured":"Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, et al. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU Int. 2015;116(1):72\u20138.","journal-title":"BJU Int"},{"issue":"1","key":"2303_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12957-020-01877-w","volume":"18","author":"X Li","year":"2020","unstructured":"Li X, Cui M, Gu X, Fang D, Li H, Qin S, Yang K, Zhu T, Li X, Zhou L, et al. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma. World J Surg Oncol. 2020;18(1):114.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"2303_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bju.12369","volume":"113","author":"LA Kluth","year":"2014","unstructured":"Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Dalpiaz O, Zigeuner R, Aziz A, et al. Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int. 2014;113(6):911\u20137.","journal-title":"BJU Int"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02303-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T14:11:21Z","timestamp":1689689481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02303-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02303-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We performed a retrospective review of data from patients at Peking Union Medical College Hospital under a study approved by the ethics committee of Peking Union Medical College Hospital, Beijing, China, in accordance with the guidelines of the Declaration of Helsinki (S-K899). Informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}